Podcasts | Accessible conversations on pharma's hot topics

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Patients

pharmaphorum podcast Episode 262, Lee-Ann Farrell, Johnson & Johnson

Towards a healthier world: Momentum in UK health system tran...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson.

Digital

pharmaphorum podcast Episode 261 - Kris Kaneta, Norstella

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

Patients

pharmaphorum podcast Episode, 260 - Ramy Younes, Boehringer Ingelheim

The cardio-renal-metabolic space and obesity as a chronic di...

The podcast welcomes Dr Ramy Younes, corporate VP, global head of clinical development, cardiorenalmetabolism, at Boehringer Ingelheim.

R&D

pharmaphorum podcast Episode 259, Cedrik Britten, Immatics

On the power of T-cells, with Cedrik Britten

Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.

R&D

Purity, potency, and safety – affordably – in stem cell ther...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s

Digital

The art of software

Harnessing the power of technology seems to be on the agenda for many life sciences companies these days.

Oncology

Move over CAR-T: The potential of NK cells in cell therapy

The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

Digital

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

Digital

BIO-Europe Spring podcast with Kashif Sadiq

Creating what nature has not from AI and computational molec...

Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Oncology

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology